Shelby Research LLC | Memphis, TN

Research site

(Unclaimed)

Location

6005 Park Ave, suite 409, Memphis, Tennessee, United States of America

Site insights

Top conditions

Top treatments

Ianalumab

BI 3000202

Afimetoran

MT-7117

Cenerimod

Upadacitinib

KPG-818

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 11 total trials

A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome. (NEPTUNUS-Ext)

The purpose of this study is to measure the long-term safety and tolerability of ianalumab in participants with Sjögren's syndrome who have previousl...

Active, not recruiting

Sjogrens Syndrome

Other: Placebo

Drug: Ianalumab (VAY736)

A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus (OPUS-1)

The goal of this clinical trial is to see how well cenerimod reduces symptoms of Systemic Lupus Erythematosus in adult patients with moderate to seve...

Active, not recruiting

Lupus Erythematosus, Systemic

Drug: Placebo

Drug: Cenerimod

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Active, not recruiting

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

Locations recently updated

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

This study is open to adults with systemic lupus erythematosus (SLE). The purpose of this study is to find out whether a medicine called BI 3000202 h...

Enrolling

Systemic Lupus Erythematosus

Drug: Placebo

Drug: BI 3000202

Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). (SIRIUS-SLE LTE)

The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have pr...

Enrolling

Systemic Lupus Erythematosus

Drug: Placebo

Drug: Ianalumab

Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)

The trial will evaluate efficacy, safety and tolerability of two regimens of ianalumab compared to placebo, given as monthly or quarterly subcutaneou...

Active, not recruiting

Systemic Lupus Erythematosus

Drug: Placebo

Drug: Ianalumab

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE)

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Active, not recruiting

Systemic Lupus Erythematosus

Drug: Upadacitinib

Drug: Placebo

Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

The purpose of this study is to demonstrate the comparability of ianalumab exposure following the sub-cutaneous (s.c.) administration of one injectio...

Active, not recruiting

Sjögrens Disease

Systemic Lupus Erythematosus

Biological: VAY736 2ml AI

Biological: VAY736 1ml PFS